MedTrace Logo

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

NCT02939820 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2024-05-20

No results posted yet for this study

Summary

The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).

Conditions

  • TTR-mediated Amyloidosis
  • Amyloidosis, Hereditary
  • Amyloid Neuropathies, Familial
  • Familial Amyloid Polyneuropathies
  • Amyloid Neuropathies
  • Amyloidosis, Hereditary, Transthyretin-Related

Interventions

DRUG

patisiran (ALN-TTR02)

patisiran (ALN-TTR02) administered by intravenous (IV) infusion

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Alnylam Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02939820 on ClinicalTrials.gov